CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing… Read more
Market Cap & Net Worth: CARsgen Therapeutics Holdings Limited (CRTHF)
CARsgen Therapeutics Holdings Limited (PINK:CRTHF) has a market capitalization of $416.12 Million ($416.12 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #13567 globally and #5598 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CARsgen Therapeutics Holdings Limited's stock price $0.76 by its total outstanding shares 547524155 (547.52 Million).
CARsgen Therapeutics Holdings Limited Market Cap History: 2018 to 2025
CARsgen Therapeutics Holdings Limited's market capitalization history from 2018 to 2025. Data shows change from $2.63 Billion to $416.12 Million (-24.04% CAGR).
CARsgen Therapeutics Holdings Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CARsgen Therapeutics Holdings Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
10.55x
CARsgen Therapeutics Holdings Limited's market cap is 10.55 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $2.63 Billion | $1.14 Billion | $142.80 Million | 2.31x | 18.40x |
| 2024 | $416.12 Million | $39.42 Million | -$798.13 Million | 10.55x | N/A |
Competitor Companies of CRTHF by Market Capitalization
Companies near CARsgen Therapeutics Holdings Limited in the global market cap rankings as of March 19, 2026.
Key companies related to CARsgen Therapeutics Holdings Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CARsgen Therapeutics Holdings Limited Historical Marketcap From 2018 to 2025
Between 2018 and today, CARsgen Therapeutics Holdings Limited's market cap moved from $2.63 Billion to $ 416.12 Million, with a yearly change of -24.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $416.12 Million | 0.00% |
| 2024 | $416.12 Million | -54.49% |
| 2023 | $914.37 Million | -10.22% |
| 2022 | $1.02 Billion | -61.25% |
| 2019 | $2.63 Billion | 0.00% |
| 2018 | $2.63 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of CARsgen Therapeutics Holdings Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $416.12 Million USD |
| MoneyControl | $416.12 Million USD |
| MarketWatch | $416.12 Million USD |
| marketcap.company | $416.12 Million USD |
| Reuters | $416.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.